Brief: Enzychem Lifesciences Announces Positive Results For Phase 2 U.S. Study Of EC-18 In Chemoradiation-Induced Oral Mucositis

Enzychem Lifesciences

20/10/2021 13:08

Oct 20 (Reuters) - Enzychem Lifesciences Corp  183490.KQ :
    * ENZYCHEM LIFESCIENCES ANNOUNCES POSITIVE RESULTS FOR PHASE
2
U.S. STUDY OF EC-18 IN CHEMORADIATION-INDUCED ORAL MUCOSITIS
    * ENZYCHEM LIFESCIENCES CORP - EC-18 REDUCES DURATION AND
INCIDENCE OF SEVERE ORAL MUCOSITIS IN HEAD AND NECK CANCER
PATIENTS
    * ENZYCHEM LIFESCIENCES - EC-18 SUCCESSFULLY MET BOTH
PRIMARY AND
SECONDARY ENDPOINTS IN TERMS OF EFFICACY AND SAFETY IN PHASE 2
U.S. STUDY
    * ENZYCHEM LIFESCIENCES - NO SERIOUS ADVERSE EVENTS WERE
REPORTED
BETWEEN PLACEBO AND EC-18 GROUPS AND NONE OF SAES WERE RELATED
TO EC-18
    * ENZYCHEM LIFESCIENCES - SAFETY IN PHASE 2 STUDY COMPARABLE
ACROSS ARMS WITH ALL ADVERSE EVENTS ATTRIBUTABLE TO EXPECTED
CHEMORADIATION-RELATED TOXICITY
    * ENZYCHEM LIFESCIENCES - BASED ON POSITIVE PHASE 2 DATA,
PLANS TO
FILE FOR BREAKTHROUGH THERAPY DESIGNATION TO FDA LATER THIS YEAR

Source text for Eikon:  ID:nBw8PwD2qa 
Further company coverage:  183490.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))